Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Shaffer who wrote (322)	1/5/1998 8:36:00 PM
From: Douglas	Read Replies (1) \| Respond to of 455

Hello, Dan Paramount Capital holds the control rights on most of the activities of Procept under a 1997 Purchase Agreement, including but not limited to, rights over issuance of equity securities, borrowing of money, expenditures and acquisitions. Paramount Capital can nominate a majority of the voting members of Procept's Board of Directors. Michael Weiss of Paramount Capital is the current Chairman of the Board. The "good people" are Paramount's selection. Let's hope they bring something of value to this company. Only Paramount Capital knows where this ship is headed! You can go to Paramount's homepage at: paramountcapital.com I'm still holding my stock, but not adding to my position. Still waiting on a financing announcement. Still think that Procept has allot to offer, but they need to master the art of investor relations. Too little is communicated! Have a great year. Doug.